A standalone phase 3 study of LYR-210 in China
Latest Information Update: 18 Aug 2022
Price :
$35 *
At a glance
- Drugs Mometasone (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- 18 Aug 2022 New trial record
- 11 Aug 2022 According to a LianBio media release, the company plans to conduct this trial to support regulatory approval in China.